Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.

Ther Adv Med Oncol · 2023 · PMC10052589 · PMID 37007633

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

OS data are not yet mature; while analyses appeared to favor nivolumab plus chemotherapy, this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.